Epigenetic markers in newly diagnosed breast cancer
Part of Cancer, Skin clinical trials.
This study looks at specific molecules in the body that can change how your genes work (epigenetic mediators) in women who have just been diagnosed with breast cancer. The goal is to understand these markers better, which could help improve treatment in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an Egyptian woman.
- You are 18 years old or older.
- You have been newly diagnosed with breast cancer.
- You do not have any blood disorders.
- You have never had any type of cancer other than breast cancer.
- You do not have liver cirrhosis or diseases of the uterus or bladder.
- Your breast cancer has not spread to distant parts of your body (no metastases).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at substances in your blood (metabolites) to see if they are linked to breast cancer risk, how well treatment works, and long-term outcomes. It has three groups: women without breast cancer, newly diagnosed patients getting standard therapy, and those who have finished treatment.
This study looks at the genetic and protein markers of early breast cancer in Pakistani women. It aims to understand the disease better and possibly guide future treatments.
This study looks for new lab “markers” that may help predict how breast cancer is likely to behave over time. Your tumor or health information may be used to find factors that can guide doctors’ predictions.
This study looks at proteins and imaging patterns (from tissue, fluid near the tumor, and blood) to better understand breast cancer markers. It may help researchers find clues that doctors can use to evaluate breast nodules and newly diagnosed invasive breast cancer.
This trial uses a special blood test to track cancer signals (called ctDNA) during and after treatment for early breast cancer. It aims to see whether monitoring these signals can help guide follow-up and treatment decisions.
This study looks at “selenoproteins” (protein markers in the body) to understand how triple-negative breast cancer behaves and whether they could be targets for future treatments. You may be asked to provide samples before any cancer drug treatment to see if these markers predict outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.